JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A1888 TRAM-34

Target: Calcium-Activated Potassium (KCa) Channels

Summary: KCa3.1 blocker,potent and highly selective

insoluble in H2O; insoluble in EtOH; ≥17.25 mg/mL
A5354 Zonisamide

Target: Voltage-gated Sodium (NaV) Channels|Voltage-gated Calcium Channels (CaV)|Carbonic Anhydrases|Calcium-Activated Potassium (KCa) Channels

Summary: Antiepileptic with anticonvulsant and mechanistic effect

insoluble in H2O; ≥8.35 mg/mL
A1174 AMG-517

Target: TRP Channel

Summary: TRPV1 antagonist,potent and highly selective

≥21.5 mg/mL
A8435 Furosemide

Target: Na /K /Cl- Symporters (NKCCs)|GABAA Receptors

Summary: GABAA receptors antagonist
A8549 LY335979 (Zosuquidar 3HCL)
1 Citation

Target: P-glycoprotein (P-gp)

Summary: Pgp (P-glycoprotein) inhibitor

insoluble in EtOH; ≥17.1 mg/mL
A8637 IOWH-032

Target: CFTR

Summary: CFTR inhibitor

≥21.85 mg/mL
B3041 BTB06584

Target: F1 Fo-ATPase

Summary: F1F0 ATP synthases

≥17.05 mg/mL
B4798 Procainamide HCl

Target: DNA Methyltransferases

Summary: sodium channel blocker

≥13.65 mg/mL
B1531 (R)-baclofen

Target: GABAB Receptors

Summary: GABA receptor agonist

insoluble in DMSO; insoluble in EtOH; ≥7.13 mg/mL
B2193 Mitiglinide Calcium

Target: Inward Rectifier Potassium (Kir) Channels

Summary: Potassium channel inhibitor

≥33.45 mg/mL